Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-22-026561
Filing Date
2022-05-02
Accepted
2022-05-02 21:49:32
Documents
1
Period of Report
2022-04-28

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5912
  Complete submission text file 0001209191-22-026561.txt   7320
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CYTOKINETICS, INCORPORATED 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Bhanji Muna (Reporting) CIK: 0001846905 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37766 | Film No.: 22884366